Movement Alert｜Madrigal Pharmaceuticals Falls 5.07% in Regular Trading, Q2 Earnings Loss Widening Extends Selling Pressure

Market Focus07-31

On July 31, Madrigal Pharmaceuticals declined 5.07% in regular trading, trading at $468.38 per share with turnover of $84.64 million, extending the prior session's sharp selloff.

The continued decline stems from the company's Q2 earnings report released on July 30. While core product Rezdiffra delivered net sales of $364.3 million, representing 71% year-over-year growth, and total revenue of $364.3 million exceeded the $353 million analyst consensus, the market focused on deteriorating profitability. The quarterly net loss reached $57.94 million, with EPS loss of $1.99 widening 4.74% from $1.90 a year earlier. As of June 30, more than 49,000 patients were on Rezdiffra, more than doubling from the prior year. Despite the top-line beat and better-than-expected EPS loss versus the $2.50 consensus estimate, investor concerns over the pace of margin improvement triggered sustained selling pressure that carried into a second consecutive session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1190573768?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190573768","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Madrigal Pharmaceuticals Falls 5.07% in Regular Trading, Q2 Earnings Loss Widening Extends Selling Pressure","media":"Market Focus","content":"<p><p>On July 31, Madrigal Pharmaceuticals declined 5.07% in regular trading, trading at $468.38 per share with turnover of $84.64 million, extending the prior session's sharp selloff.</p><p>The continued decline stems from the company's Q2 earnings report released on July 30. While core product Rezdiffra delivered net sales of $364.3 million, representing 71% year-over-year growth, and total revenue of $364.3 million exceeded the $353 million analyst consensus, the market focused on deteriorating profitability. The quarterly net loss reached $57.94 million, with EPS loss of $1.99 widening 4.74% from $1.90 a year earlier. As of June 30, more than 49,000 patients were on Rezdiffra, more than doubling from the prior year. Despite the top-line beat and better-than-expected EPS loss versus the $2.50 consensus estimate, investor concerns over the pace of margin improvement triggered sustained selling pressure that carried into a second consecutive session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Madrigal Pharmaceuticals Falls 5.07% in Regular Trading, Q2 Earnings Loss Widening Extends Selling Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Madrigal Pharmaceuticals Falls 5.07% in Regular Trading, Q2 Earnings Loss Widening Extends Selling Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 22:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, Madrigal Pharmaceuticals declined 5.07% in regular trading, trading at $468.38 per share with turnover of $84.64 million, extending the prior session's sharp selloff.</p><p>The continued decline stems from the company's Q2 earnings report released on July 30. While core product Rezdiffra delivered net sales of $364.3 million, representing 71% year-over-year growth, and total revenue of $364.3 million exceeded the $353 million analyst consensus, the market focused on deteriorating profitability. The quarterly net loss reached $57.94 million, with EPS loss of $1.99 widening 4.74% from $1.90 a year earlier. As of June 30, more than 49,000 patients were on Rezdiffra, more than doubling from the prior year. Despite the top-line beat and better-than-expected EPS loss versus the $2.50 consensus estimate, investor concerns over the pace of margin improvement triggered sustained selling pressure that carried into a second consecutive session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1190573768","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190573768","pubTimestamp":1785506988,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, Madrigal Pharmaceuticals declined 5.07% in regular trading, trading at $468.38 per share with turnover of $84.64 million, extending the prior session's sharp selloff.The continued decline...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc."},"translate_title":"走势警报|牧歌制药常规交易下跌5.07%，第二季度盈利亏损扩大，抛售压力扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"On July 31, Madrigal Pharmaceuticals declined 5.07% in regular trading, trading at $468.38 per share with turnover of $84.64 million, extending the prior session's sharp selloff.The continued decline stems from the company's Q2 earnings report released on July 30. While core product Rezdiffra delivered net sales of $364.3 million, representing 71% year-over-year growth, and total revenue of $364.3 million exceeded the $353 million analyst consensus, the market focused on deteriorating profitability. The quarterly net loss reached $57.94 million, with EPS loss of $1.99 widening 4.74% from $1.90 a year earlier. As of June 30, more than 49,000 patients were on Rezdiffra, more than doubling from the prior year. Despite the top-line beat and better-than-expected EPS loss versus the $2.50 consensus estimate, investor concerns over the pace of margin improvement triggered sustained selling pressure that carried into a second consecutive session.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190573768","isCrawlerRequest":true}